

IN THE SPECIFICATION:

Please incorporate the enclosed underlined paper copy of the substitute SEQUENCE LISTING into the application after the specification and before the claims.

Column 9, para. 3. (Amended) 3) Peptide formula of N-tandem-LHRH-dimer (SEQ ID NO:6 where residues 7 and 17 are Gly and residue 21 is glycine amide):

E<sup>1</sup>

1	21
CQHWSYGLRPGQHWSYGLRPG@	
CQHWSYGLRPGQHWSYGLRPG@	
22	42

IN THE CLAIMS:

5. (Twice Amended) A peptide according to claim 3 and having the structure (SEQ ID NO: 7 where residue 22 is Cys):

E<sup>2</sup>

<u>1</u> [1]	[6] <u>7</u>	[16] <u>17</u>	[21] <u>22</u>
#CQHWSY*LRPGQHWSY*LRPGC			
#CQHWSY*LRPGQHWSY*LRPGC			
<u>23</u> [22]	[27] <u>29</u>	[37] <u>39</u>	[42] <u>44</u>

wherein the amino acid \* at position [6 or 16 or 27 or 37] 7 or 17 or 29 or 39 is D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be coupled to a carrier compound and the other amino acid \* is either glycine or D-lysine or D-glutamine or another dextrorotatory amino acid with a side chain that can be couple to a carrier compound.